Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Efficacy and Benefit of Reducing Metabolic Syndrome by Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics (MARTAs) Treated Schizophrenia Patients

NCT04898270 is registered in ClinicalTrials.gov with Taichung Veterans General Hospital as lead sponsor.

NCT NCT04898270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04898270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Efficacy and Benefit of Reducing Metabolic Syndrome by Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics (MARTAs) Treated Schizophrenia Patients
Lead sponsor
Taichung Veterans General Hospital
Phase
Phase 4
Overall status
Completed
Start date
December 19, 2019
Completion date
April 20, 2021
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antipsychotic agents, central nervous system diseases, clinical therapy, flupentixol, metabolic syndrome, olanzapine, quetiapine, schizophrenia; psychosis